Regeneron Pharmaceuticals
REGN
644 hedge funds and large institutions have $29.8B invested in Regeneron Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 216 increasing their positions, 225 reducing their positions, and 54 closing their positions.
46% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 54
19% more capital invested
Capital invested by funds: $25B → $29.8B (+$4.73B)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
3% more funds holding
Funds holding: 624 → 644 (+20)
0.83% more ownership
Funds ownership: 68.66% → 69.48% (+0.83%)
4% less repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 225
35% less call options, than puts
Call options by funds: $756M | Put options by funds: $1.16B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$662M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$277M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$123M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$103M |
| 5 |
Morgan Stanley
New York
|
+$73.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$142M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$117M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$115M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$99.2M |
| 5 |
MNG
Manning & Napier Group
Fairport,
New York
|
-$94.5M |
REGN Hedge Fund Activity: Q3 2018 in Review
644 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2018, worth a combined $29.8B — up 19% from $25B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new REGN positions and 54 closed out — a net gain of 25 holders — while 216 added to existing stakes and 225 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $662M. The largest seller was Two Sigma Investments, cutting an estimated $142M.
- 644 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2018, up from 624 in Q2 2018.
- Funds reported $29.8B of Regeneron Pharmaceuticals stock for Q3 2018, up 19% quarter-over-quarter.
- 79 funds opened new Regeneron Pharmaceuticals positions in Q3 2018 and 54 closed out, a net change of +25 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2018 was Capital International Investors, an estimated $662M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2018 was Two Sigma Investments, an estimated $142M sold.
Based on aggregated 13F filings for Q3 2018.